Status:
TERMINATED
Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine Tumours
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Non-resectable Metastatic Cancer of the Lung
Non-resectable Metastatic Cancer of the Colon
Eligibility:
All Genders
Brief Summary
Reflexion on the therapeutic strategies to implement in patients at the end of life is advancing rapidly in France. However, beyond the choices presented to patients, sometimes even the decision to ca...
Eligibility Criteria
Inclusion
- I- PATIENTS
- men or women
- who have been informed about the study
- and who have provided verbal consent to take part in the study
- able to understand written and spoken French
- with non-resectable metastatic cancer of: the colon, or the rectosigmoid junction or the stomach or bile ducts or rectum or gastrointestinal neuroendocrine tumor or lung (not small-cell cancer) or pancreas
- with a caregiver designated as the principal caregiver (family, friend, neighbour)
- who has consented to the principal caregiver taking part in a qualitative interview
- able to take part in an interview lasting roughly one hour
- II- CAREGIVERS
- men or women
- who have been informed about the study
- who have provided verbal consent to take part in the study
- able to understand written and spoken French
- able to follow an interview lasting roughly one hour
- III-DOCTORS
- men or women
- who have been informed about the study
- who have provided verbal consent to take part in the study
- specialised in specific organ or oncologist prescriber
Exclusion
- I- PATIENTS
- under guardianship or ward of court
- with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis, severe mental retardation etc.)
- II- CAREGIVERS
- under guardianship or ward of court,
- with a severe handicap (neurological disease: Parkinson, Alzheimer, other dementia, multiple sclerosis…),
- with severe mental retardation impairing ability to understand.
Key Trial Info
Start Date :
December 19 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 19 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03328065
Start Date
December 19 2017
End Date
December 19 2020
Last Update
April 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourogne
Dijon, France, 21000